International medtechs seeking to sell in China must learn to factor in its increasingly aggressive industrial and investment policies. The private sector is very small in China, and the scale of its state-based procurement and industrial subsidies programs makes it hard for foreign companies to compete effectively.
There is much for multinationals be alert to in China, as in many other markets of the world where price-based competition remains the main business driver in medtech. That was...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?